Discovery and development of gliflozins/ja: Difference between revisions

← Older edit

VisualWikitext

@@ Line 72: / Line 72: @@
 [[File:Mynd fyrir toflu1.png]]
-<div lang="en" dir="ltr" class="mw-content-ltr">
 {| class="wikitable"
 |-
-! R !! IC<sub>50</sub> (nM) !! Activity
+! R !! IC<sub>50</sub> (nM) !! 活性
 |-
-|align="center"| [[File:Bygging 1.png]] ||align="center"| 0.720 ||align="center"| ''in vitro'' activity improved*
+|align="center"| [[File:Bygging 1.png]] ||align="center"| 0.720 ||align="center"| ''試験管内''活性が向上*
 |-
-|align="center"| [[File:Bygging 2.png]] ||align="center"| 1.14 ||align="center"| ''in vitro'' activity improved*
+|align="center"| [[File:Bygging 2.png]] ||align="center"| 1.14 ||align="center"| ''試験管内''活性が向上*
 |-
-|align="center"| [[File:Bygging 3.png]] ||align="center"| 13.3 ||align="center"| As the number of carbons increases, the IC-50 value fluctuates
+|align="center"| [[File:Bygging 3.png]] ||align="center"| 13.3 ||align="center"| 炭素数が増えるにつれて、IC-50値は変動
 |-
-|align="center"| [[File:1-Methoxy-n-butane.png]] ||align="center"| 19.6 ||align="center"| ''in vitro'' activity decreased*
+|align="center"| [[File:1-Methoxy-n-butane.png]] ||align="center"| 19.6 ||align="center"| ''試験管内''での''活性が低下*
 |-
-|align="center"| [[File:Bygging 5.png]] ||align="center"| 21.2 ||align="center"| ''in vitro'' activity decreased*
+|align="center"| [[File:Bygging 5.png]] ||align="center"| 21.2 ||align="center"| ''試験管内''での''活性が低下*
 |}
-''*comparator to ethyl group (IC<sub>50</sub> = 16,7)''
+''*エチル基との比較対象 (IC<sub>50</sub> = 16,7)''
-</div>
-<div lang="en" dir="ltr" class="mw-content-ltr">
+表2において、''試験管内''活性は、近位フェニル環（X）のC-4領域の化合物によって変化する。C-4位に小さなメチル基や他のハロゲン原子があると、IC<sub>50</sub>は0.72-36.7の範囲になった（2-フリルを持つフェニルが環の位置にあることを考慮）。
-In table 2, the ''in vitro'' activity changes depending on the compound in the C-4 region of the proximal phenyl ring (X). Small methyl groups or other halogen atoms in the C-4 position gave IC<sub>50</sub> ranging from 0.72–36.7 (given that the phenyl with 2-furyl is in the ring position).
-</div>
-<div lang="en" dir="ltr" class="mw-content-ltr">
+'''表2：'''近位フェニル環のC-4領域にどの化合物があるかによる'''試験管内'''活性の違い。
-'''Table 2:''' Differences in ''in vitro'' activity depending on what compound is in the C-4 region of the proximal phenyl ring.
-</div>
-<div lang="en" dir="ltr" class="mw-content-ltr">
 [[File:Mynd fyrir toflu2.png]]
-</div>
-<div lang="en" dir="ltr" class="mw-content-ltr">
 {| class="wikitable"
 |-
@@ Line 117: / Line 108: @@
 |align="center"| CN ||align="center"| 36.7
 |}
-</div>
-<div lang="en" dir="ltr" class="mw-content-ltr">
+'''表3：'''チアゾール環の関わり方によるIC<sub>50</sub>値の違い（他の構造は何も変えていない（X = Cl, R = フェニルと2-フリル）。
-'''Table 3:''' Difference in the IC<sub>50</sub> value depending on how the thiazole ring relates (nothing else is changed in the structure (X = Cl, R = phenyl with 2-furyl).
 {| class="wikitable"
 |-
-! Compound !! IC<sub>50</sub> (nM)
+! 化合物 !! IC<sub>50</sub> (nM)
 |-
 |align="center"| [[File:Mynd fyrir toflu3-1.png]] ||align="center"| 0.720
@@ Line 129: / Line 118: @@
 |align="center"| [[File:Mynd fyrir toflu3-2.png]] ||align="center"| 1.11
 |}
-</div>
-<div lang="en" dir="ltr" class="mw-content-ltr">
+== こちらも参照 ==
-== See also ==
+* [[Sodium-glucose transport proteins/ja]]
-* [[Sodium-glucose transport proteins]]
+* [[SLC5A2/ja]]
-* [[SLC5A2]]
+* [[SGLT1/ja]]
-* [[SGLT1]]
+* [[SGLT2/ja]]
-* [[SGLT2]]
+* [[Dapagliflozin/ja]]
-* [[Dapagliflozin]]
+* [[Empagliflozin/ja]]
-* [[Empagliflozin]]
+* [[Canagliflozin/ja]]
-* [[Canagliflozin]]
+* [[Ipragliflozin/ja]]
-* [[Ipragliflozin]]
-</div>
-<div lang="en" dir="ltr" class="mw-content-ltr">
+{{Drug design/ja}}
-{{Drug design}}
-</div>
-<div lang="en" dir="ltr" class="mw-content-ltr">
-{{二次利用|date=29 August 2023}}
 [[Category:Drug discovery|Gliflozins]]
 [[Category:SGLT2 inhibitors| ]]
-</div>